• news.cision.com/
  • Vigmed/
  • Statement by Vigmed’s bid committee in relation to the increased public offer by Greiner Bio-One
English

Statement by Vigmed’s bid committee in relation to the increased public offer by Greiner Bio-One

Report this content

Helsingborg, 20 April 2017
 
The independent Vigmed Bid Committee continues to recommend the shareholders to accept the Greiner Bio-One’s public offer. 

On 27 February 2017, Greiner Bio-One GmbH (“GBO”) announced a public cash offer to the shareholders of Vigmed Holding AB (publ) (“Vigmed”) at the price of SEK 1.00 in cash per share (the “Offer”).

On 13 April 2917, GBO announced its decision to increase the Offer consideration to SEK 1.20 in cash per share[1]. The total value of the increased Offer, based on all outstanding 65,749,998 shares in Vigmed, amounts to approximately SEK 78.9 million.
The increased Offer represents a premium of[2]:

  • 3.4 per cent compared to the volume-weighted average trading price over the 30 calendar days ending on 24 February 2017 of SEK 1.16 for the Vigmed share; and
  • 21.2 per cent compared to the closing price of SEK 0.99 for the Vigmed share on 24 February 2017, the last day of trading prior to the announcement of the Offer.

In addition, GBO announced on 13 April 2017 its decision to extend the acceptance period until and including 27 April 2017 at 5:00 p.m. CEST, and that all conditions for completion of the Offer would remain unchanged, including, inter alia, the Offer being accepted to such extent that GBO becomes the owner of more than 90 percent of all shares in Vigmed[3].

The independent bid committee appointed by the Vigmed board (the “Bid Committee”)[4] has previously on 27 February 2017 and on 10 April 2017 unanimously recommended the shareholders of Vigmed to accept the Offer of SEK 1.00 per share. For information on the assessment of the Bid Committee on the impact that the completion of the Offer may have on Vigmed, especially employment, and its views on GBO’s strategic plans for Vigmed and the impact that these could have on employment and on the locations where Vigmed operates its business, as well as the Bid Committee’s view on the financing proposal announced by Beijing Topraise Medical Technology and its partner, please refer to the Bid Committee’s statements of 27 February 2017 and on 10 April 2017, which are available on https://se.vigmed.com/investor/uppkoepserbjudande.aspx.

The increase of the consideration of the Offer does not change assessments and views the Bid Committee as announced previously, and, accordingly, the Bid Committee repeats, unanimously, its recommendation that the shareholders of Vigmed accept the Offer from GBO.

___________________

This statement shall in all respects be governed by and construed in accordance with substantive Swedish law. Any dispute arising from this statement shall be exclusively settled by Swedish courts, and the Stockholm District Court (Sw. Stockholms tingsrätt) shall be the court of first instance.
___________________

Helsingborg, 20 April 2017
Vigmed Holding AB (publ)
The Bid Committee

--------------------------

This announcement was submitted for publication at 08.00 am CET on 20 April 2017.


For further information, contact:
Sten Dahlborg, Chairman of the Board of Directors and the Bid Committee,
+46 708-369 419, budkommitte@vigmed.com

[1] The consideration under the Offer will be reduced accordingly should Vigmed, prior to the settlement of the Offer, distribute a dividend or in any other way distribute or transfer value to its shareholders.
[2] Source for Vigmed share prices: Capital IQ.
[3] GBO has reserved the right to fully or partially waive this and other conditions to completion of the Offer. For further information regarding the Offer, please refer to GBOs Offer announcement.
[4] The Bid Committee consists of Board Sten Dahlborg (Chairman), Thomas Baier and Axel Sjöblad, which have no conflict of interest in relation to the GBO or Offer.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor

Tags:

Vigmed

Documents & Links